Estimating stable isotope turnover rates of epidermal mucus and dorsal muscle for an omnivorous fish using a diet-switch experiment

© 2018, The Author(s). Stable isotope (SI) analysis studies rely on knowledge of isotopic turnover rates and trophic-step discrimination factors. Epidermal mucus (‘mucus’) potentially provides an alternative SI ‘tissue’ to dorsal muscle that can be collected non-invasively and non-destructively. Here, a diet-switch experiment using the omnivorous fish Cyprinus carpio and plant- and fish-based formulated feeds compared SI data between mucus and muscle, including their isotopic discrimination factors and turnover rates (as functions of time T and mass G, at isotopic half-life (50) and equilibrium (95)). Mucus isotope data differed significantly and predictively from muscle data. The fastest δ13C turnover rate was for mucus in fish on the plant-based diet (T50: 17 days, T95: 74 days; G50: 1.08(BM), G95: 1.40(BM)). Muscle turnover rates were longer for the same fish (T50: 44 days, T95: 190 days; G50: 1.13(BM), G95: 1.68(BM)). Longer half-lives resulted in both tissues from the fish-based diet. δ13C discrimination factors varied by diet and tissue (plant-based: 3.11–3.28‰; fishmeal: 1.28–2.13‰). Mucus SI data did not differ between live and frozen fish. These results suggest that mucus SI half-lives provide comparable data to muscle, and can be used as a non-destructive alternative tissue in fish-based SI studies

Three long period transiting giant planets from TESS

We report the discovery and orbital characterization of three new transiting warm giant planets. These systems were initially identified as presenting single transit events in the light curves generated from the full frame images of the Transiting Exoplanet Survey Satellite (TESS). Follow-up radial velocity measurements and additional light curves were used to determine the orbital periods and confirm the planetary nature of the candidates. The planets orbit slightly metal-rich late F- and early G-type stars. We find that TOI 4406b has a mass of $M_P$= 0.30 $\pm$ 0.04 $M_J$ , a radius of $R_P$= 1.00 $\pm$ 0.02 $R_J$ , and a low eccentricity orbit (e=0.15 $\pm$ 0.05) with a period of P= 30.08364 $\pm$ 0.00005 d . TOI 2338b has a mass of $M_P$= 5.98 $\pm$ 0.20 $M_J$ , a radius of $R_P$= 1.00 $\pm$ 0.01 $R_J$ , and a highly eccentric orbit (e= 0.676 $\pm$ 0.002 ) with a period of P= 22.65398 $\pm$ 0.00002 d . Finally, TOI 2589b has a mass of $M_P$= 3.50 $\pm$ 0.10 $M_J$ , a radius of $R_P$= 1.08 $\pm$ 0.03 $R_J$ , and an eccentric orbit (e = 0.522 $\pm$ 0.006 ) with a period of P= 61.6277 $\pm$ 0.0002 d . TOI 4406b and TOI 2338b are enriched in metals compared to their host stars, while the structure of TOI 2589b is consistent with having similar metal enrichment to its host star.Comment: 24 pages, 16 figures, accepted in A

TOI-199 b: A well-characterized 100-day transiting warm giant planet with TTVs seen from Antarctica

We present the spectroscopic confirmation and precise mass measurement of the warm giant planet TOI-199 b. This planet was first identified in TESS photometry and confirmed using ground-based photometry from ASTEP in Antarctica including a full 6.5$\,$h long transit, PEST, Hazelwood, and LCO; space photometry from NEOSSat; and radial velocities (RVs) from FEROS, HARPS, CORALIE, and CHIRON. Orbiting a late G-type star, TOI-199\,b has a $\mathrm{104.854_{-0.002}^{+0.001} \, d}$ period, a mass of $\mathrm{0.17\pm0.02 \, M_J}$, and a radius of $\mathrm{0.810\pm0.005 \, R_J}$. It is the first warm exo-Saturn with a precisely determined mass and radius. The TESS and ASTEP transits show strong transit timing variations, pointing to the existence of a second planet in the system. The joint analysis of the RVs and TTVs provides a unique solution for the non-transiting companion TOI-199 c, which has a period of $\mathrm{273.69_{-0.22}^{+0.26} \, d}$ and an estimated mass of $\mathrm{0.28_{-0.01}^{+0.02} \, M_J}$. This period places it within the conservative Habitable Zone.Comment: 33 pages, 23 figures. Accepted for publication in A

A long-period transiting substellar companion in the super-Jupiters to brown dwarfs mass regime and a prototypical warm-Jupiter detected by TESS

We report on the confirmation and follow-up characterization of two long-period transiting substellar companions on low-eccentricity orbits around TIC 4672985 and TOI-2529, whose transit events were detected by the TESS space mission. Ground-based photometric and spectroscopic follow up from different facilities, confirmed the substellar nature of TIC 4672985 b, a massive gas giant, in the transition between the super-Jupiters and brown-dwarfs mass regime. From the joint analysis we derived the following orbital parameters: P = 69.0480+0.0004−0.0005 d, Mp = 12.74+1.01−1.01 MJ, Rp =1.026+0.065−0.067 RJ and e = 0.018+0.004−0.004 . In addition, the RV time series revealed a significant trend at the ∼ 350 m s−1 yr−1level, which is indicative of the presence of a massive outer companion in the system. TIC 4672985 b is a unique example of a transiting substellar companion with a mass above the deuterium-burning limit, located beyond 0.1 AU and in a nearly circular orbit. These planetary properties are difficult to reproduce from canonical planet formation and evolution models. For TOI-2529 b, we obtained the following orbital parameters: P = 64.5949+0.0003−0.0003 d, Mp =2.340+0.197−0.195 MJ, Rp = 1.030+0.050−0.050 RJ and e = 0.021+0.024−0.015 , making this object a new example of a growing population of transiting warm giant planets

Functional antibody and T-cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study (NCT03226886) integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2-positive, 94 were symptomatic and 2 patients died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies, 82% had neutralizing antibodies against WT, whereas neutralizing antibody titers (NAbT) against the Alpha, Beta, and Delta variants were substantially reduced. Whereas S1-reactive antibody levels decreased in 13% of patients, NAbT remained stable up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment-specific, but presented compensatory cellular responses, further supported by clinical. Overall, these findings advance the understanding of the nature and duration of immune response to SARS-CoV-2 in patients with cancer

Prevalence and architecture of de novo mutations in developmental disorders.

The genomes of individuals with severe, undiagnosed developmental disorders are enriched in damaging de novo mutations (DNMs) in developmentally important genes. Here we have sequenced the exomes of 4,293 families containing individuals with developmental disorders, and meta-analysed these data with data from another 3,287 individuals with similar disorders. We show that the most important factors influencing the diagnostic yield of DNMs are the sex of the affected individual, the relatedness of their parents, whether close relatives are affected and the parental ages. We identified 94 genes enriched in damaging DNMs, including 14 that previously lacked compelling evidence of involvement in developmental disorders. We have also characterized the phenotypic diversity among these disorders. We estimate that 42% of our cohort carry pathogenic DNMs in coding sequences; approximately half of these DNMs disrupt gene function and the remainder result in altered protein function. We estimate that developmental disorders caused by DNMs have an average prevalence of 1 in 213 to 1 in 448 births, depending on parental age. Given current global demographics, this equates to almost 400,000 children born per year

Precise Transit and Radial-velocity Characterization of a Resonant Pair: The Warm Jupiter TOI-216c and Eccentric Warm Neptune TOI-216b

TOI-216 hosts a pair of warm, large exoplanets discovered by the TESS mission. These planets were found to be in or near the 2:1 resonance, and both of them exhibit transit timing variations (TTVs). Precise characterization of the planets’ masses and radii, orbital properties, and resonant behavior can test theories for the origins of planets orbiting close to their stars. Previous characterization of the system using the first six sectors of TESS data suffered from a degeneracy between planet mass and orbital eccentricity. Radial-velocity measurements using HARPS, FEROS, and the Planet Finder Spectrograph break that degeneracy, and an expanded TTV baseline from TESS and an ongoing ground-based transit observing campaign increase the precision of the mass and eccentricity measurements. We determine that TOI-216c is a warm Jupiter, TOI-216b is an eccentric warm Neptune, and that they librate in 2:1 resonance with a moderate libration amplitude of 60-+22 deg, a small but significant free eccentricity of 0.0222-+0.00030.0005 for TOI-216b, and a small but significant mutual inclination of 1°.2–3°.9 (95% confidence interval). The libration amplitude, free eccentricity, and mutual inclination imply a disturbance of TOI-216b before or after resonance capture, perhaps by an undetected third planet

Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.

BACKGROUND: Remote ischaemic conditioning with transient ischaemia and reperfusion applied to the arm has been shown to reduce myocardial infarct size in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). We investigated whether remote ischaemic conditioning could reduce the incidence of cardiac death and hospitalisation for heart failure at 12 months. METHODS: We did an international investigator-initiated, prospective, single-blind, randomised controlled trial (CONDI-2/ERIC-PPCI) at 33 centres across the UK, Denmark, Spain, and Serbia. Patients (age >18 years) with suspected STEMI and who were eligible for PPCI were randomly allocated (1:1, stratified by centre with a permuted block method) to receive standard treatment (including a sham simulated remote ischaemic conditioning intervention at UK sites only) or remote ischaemic conditioning treatment (intermittent ischaemia and reperfusion applied to the arm through four cycles of 5-min inflation and 5-min deflation of an automated cuff device) before PPCI. Investigators responsible for data collection and outcome assessment were masked to treatment allocation. The primary combined endpoint was cardiac death or hospitalisation for heart failure at 12 months in the intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT02342522) and is completed. FINDINGS: Between Nov 6, 2013, and March 31, 2018, 5401 patients were randomly allocated to either the control group (n=2701) or the remote ischaemic conditioning group (n=2700). After exclusion of patients upon hospital arrival or loss to follow-up, 2569 patients in the control group and 2546 in the intervention group were included in the intention-to-treat analysis. At 12 months post-PPCI, the Kaplan-Meier-estimated frequencies of cardiac death or hospitalisation for heart failure (the primary endpoint) were 220 (8·6%) patients in the control group and 239 (9·4%) in the remote ischaemic conditioning group (hazard ratio 1·10 [95% CI 0·91-1·32], p=0·32 for intervention versus control). No important unexpected adverse events or side effects of remote ischaemic conditioning were observed. INTERPRETATION: Remote ischaemic conditioning does not improve clinical outcomes (cardiac death or hospitalisation for heart failure) at 12 months in patients with STEMI undergoing PPCI. FUNDING: British Heart Foundation, University College London Hospitals/University College London Biomedical Research Centre, Danish Innovation Foundation, Novo Nordisk Foundation, TrygFonden